Tivantinib

Generic Name: Tivantinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₁₉N_₃O_₂

CAS Number: 905854-02-6

Unique Ingredient Identifier: PJ4H73IL17

Background: Tivantinib has been investigated in Solid Tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temsirolimus
Drug: Tivantinib

First Posted Date: 2012-06-21

Last Posted Date: 2015-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT01625156

Locations: 🇺🇸
Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Phase 1

Completed

Conditions: Gastroesophageal Cancer
Malignant Solid Tumour

Interventions: Drug: Tivantinib
Drug: FOLFOX

First Posted Date: 2012-06-05

Last Posted Date: 2016-11-23

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 49

Registration Number: NCT01611857

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Florida Cancer Specialists-Sarasota, Sarasota, Florida, United States
🇺🇸
Florida Cancer Specialists-North, St. Petersburg, Florida, United States

and more 6 locations

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor Negative
Recurrent Breast Carcinoma
HER2/Neu Negative
Progesterone Receptor Negative
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tivantinib

First Posted Date: 2012-04-11

Last Posted Date: 2016-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01575522

Locations: 🇺🇸
Dana-Farber Cancer Institute Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Hormone-Resistant Prostate Cancer
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tivantinib
Other: Placebo

First Posted Date: 2012-01-27

Last Posted Date: 2018-09-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT01519414

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸
University of Maryland Saint Joseph Medical Center, Towson, Maryland, United States

and more 17 locations

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: tivantinib
Drug: omeprazole
Drug: s-warfarin
Drug: caffeine
Dietary Supplement: vitamin K
Drug: digoxin
Drug: midazolam

First Posted Date: 2012-01-25

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 28

Registration Number: NCT01517399

Locations: 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: Tivantinib
Other: Diagnostic laboratory biomarker analysis
Other: Questionnaire administration
Procedure: Quality-of-life assessment

First Posted Date: 2011-10-06

Last Posted Date: 2019-08-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT01447914

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Phase 3

Terminated

Conditions: Non Squamous, Non-small-cell Lung Cancer

Interventions: Drug: Placebo
Drug: Tivantinib
Drug: Erlotinib

First Posted Date: 2010-11-19

Last Posted Date: 2021-04-06

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1048

Registration Number: NCT01244191

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Tivantinib
Drug: Anti-Cancer Combination Therapy

First Posted Date: 2010-08-10

Last Posted Date: 2021-03-10

Lead Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Target Recruit Count: 60

Registration Number: NCT01178411

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Placebo
Drug: Tivantinib
Drug: Cetuximab
Drug: Irinotecan

First Posted Date: 2010-02-24

Last Posted Date: 2021-04-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 131

Registration Number: NCT01075048

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy